Pre-irradiation Intensive Induction and Marrow-ablative Consolidation Chemotherapy in Young Children with Newly Diagnosed High-Grade Brainstem Gliomas: Report of the 'Head-Start' I and II Clinical Trials
Autor: | Joseph Stanek, Amanda M. Termuhlen, James Garvin, Neha Patel, Diana S Osorio, Jeffrey C. Allen, Ira J. Dunkel, Lingyun Ji, Richard Sposto, Geoffrey McCowage, Albert Cornelius, Sharon Gardner, Jonathan L. Finlay, Melanie Comito |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty medicine.medical_treatment ThioTEPA Kaplan-Meier Estimate Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Bone Marrow Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Brainstem glioma Brain Stem Neoplasms Humans Child Etoposide Chemotherapy business.industry Infant Newborn Infant Consolidation Chemotherapy Glioma Induction Chemotherapy medicine.disease Carboplatin Treatment Outcome Neurology chemistry 030220 oncology & carcinogenesis Head start Child Preschool Female Neurology (clinical) business 030217 neurology & neurosurgery Progressive disease medicine.drug |
Zdroj: | J Neurooncol |
Popis: | BACKGROUND: The dismal outcome in children with high-grade brainstem gliomas (BSG) accentuates the need for effective therapeutic strategies. We investigated the role of intensive, including marrow-ablative, chemotherapy regimens in the treatment of young children with newly-diagnosed high-grade BSG. METHODS: Between 1991-and-2002, 15 eligible children less than 10 years of age with a diagnosis of high-grade BSG were treated on “Head-Start” I and II protocols (HSI and HSII). Treatment included Induction with 4-5 cycles of one of three intensive chemotherapy regimens followed by Consolidation with one cycle of marrow-ablative chemotherapy (thiotepa, carboplatin and etoposide) with autologous hematopoietic cell rescue (AHCR). Irradiation was required for children over 6 years of age or for those with residual tumor at the end of Consolidation. RESULTS: We had two long-term survivors who were found retrospectively to harbor low-grade glial tumors and thus were not included in the survival analysis. Of the remaining 13 patients, the 1-year event-free (EFS) and overall (OS) survival for these children were 31% (95% CI: 9-55%) and 38% (95% CI: 14 to 63%), respectively. Median EFS and OS were 6.6 (95% CI: 2.7, 12.7) and 8.7 months (95% CI: 6.9, 20.9), respectively. Eight patients developed progressive disease during study treatment (seven during Induction and one at the end of Consolidation). Ten children received focal irradiation, five for residual tumor (three following Induction and two following Consolidation) and five due to disease progression. CONCLUSIONS: Children with high-grade BSG did not benefit from this intensive chemotherapy strategy administered prior to irradiation. |
Databáze: | OpenAIRE |
Externí odkaz: |